You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,650,387


✉ Email this page to a colleague

« Back to Dashboard


Title:Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Inventor(s): Mickle; Travis (Celebration, FL), Guenther; Sven (Coralville, IA), Mickle; Christal (Celebration, FL), Chi; Guochen (Coralville, IA), Kanski; Jaroslaw (Blacksburg, VA), Martin; Andrea K. (Fincastle, VA), Bera; Bindu (Blacksburg, VA)
Assignee: KemPharm, Inc. (Celebration, FL)
Filing Date:Mar 21, 2016
Application Number:15/076,586
Claims:1. A composition comprising 13.34 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure: ##STR00025## wherein the conjugate is provided in a gel formulation.

2. The composition of claim 1, wherein the 13.34 mg benzoate-hydrocodone hydrochloride contains a molar equivalent of 9.08 mg of hydrocodone.

3. The composition of claim 1, wherein the gel formulation further comprises a soft gel.

4. The composition of claim 1 further comprising 650 mg acetaminophen.

5. A composition comprising 26.68 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure: ##STR00026## wherein the conjugate is further provided in a gel formulation.

6. The composition of claim 5 further comprising 1300 mg acetaminophen.

7. The composition of claim 6, wherein the conjugate results in the mean C.sub.max of hydrocodone of about 75,100 pg/mL.+-.25,500 pg/mL when administered orally to a human.

8. The composition of claim 6, wherein the conjugate results in the mean T.sub.max of hydrocodone of about 1.17 hours when administered orally to a human.

9. The composition of claim 6, wherein the conjugate results in the range of T.sub.max of hydrocodone from about 0.6 hours to about 4.12 hours when administered orally to a human.

10. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-0.5h of hydrocodone of about 12,530 h.times.pg/mL.+-.7,213 h.times.pg/mL when administered orally to a human.

11. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-1h of hydrocodone of about 42,520 h.times.pg/mL.+-.20,200 h.times.pg/mL when administered orally to a human.

12. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-2h of hydrocodone of about 95,850 h.times.pg/mL.+-.29,510 h.times.pg/mL when administered orally to a human.

13. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-4h of hydrocodone of about 172,200 h.times.pg/mL.+-.39,550 h.times.pg/mL when administered orally to a human.

14. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-8h of hydrocodone of about 269,000 h.times.pg/mL.+-.51,840 h.times.pg/mL when administered orally to a human.

15. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.0-24h of hydrocodone of about 382,100 h.times.pg/mL.+-.81,260 h.times.pg/mL when administered orally to a human.

16. The composition of claim 6, wherein the conjugate results in the mean AUC.sub.inf of hydrocodone of about 392,800 h.times.pg/mL.+-.86,300 h.times.pg/mL when administered orally to a human.

17. The composition of claim 6, wherein the conjugate results in the mean t.sub.1/2 of hydrocodone of about 4.99 hours.+-.0.79 hours when administered orally to a human.

18. A composition comprising 53.36 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure: ##STR00027## wherein the conjugate is provided in a gel formulation.

19. The composition of claim 18 further comprising 2600 mg acetaminophen.

20. The composition of claim 19, wherein the conjugate results in the mean C.sub.max of hydrocodone of about 147,000 pg/mL.+-.54,100 pg/mL when administered orally to a human.

21. The composition of claim 19, wherein the conjugate results in the mean T.sub.max of hydrocodone of about 1.05 hours when administered orally to a human.

22. The composition of claim 19, wherein the conjugate results in the range of T.sub.max of hydrocodone from about 0.6 hours to about 4.12 hours when administered orally to a human.

23. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-0.5h of hydrocodone of about 26,900 h.times.pg/mL.+-.14,770 h.times.pg/mL when administered orally to a human.

24. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-1h of hydrocodone of about 88,750 h.times.pg/mL.+-.42,380 h.times.pg/mL when administered orally to a human.

25. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-21, of hydrocodone of about 193,400 h.times.pg/mL.+-.66,470 h.times.pg/mL when administered orally to a human.

26. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-4h of hydrocodone of about 353,500 h.times.pg/mL.+-.97,670 h.times.pg/mL when administered orally to a human.

27. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-8h of hydrocodone of about 566,900 h.times.pg/mL.+-.128,200 h.times.pg/mL when administered orally to a human.

28. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.0-4h of hydrocodone of about 811,900 h.times.pg/mL.+-.175,100 h.times.pg/mL when administered orally to a human.

29. The composition of claim 19, wherein the conjugate results in the mean AUC.sub.inf of hydrocodone of about 842,100 h.times.pg/mL.+-.190,800 h.times.pg/mL when administered orally to a human.

30. The composition of claim 19, wherein the conjugate results in the mean t.sub.1/2 of hydrocodone of about 4.92 hours.+-.0.95 hours when administered orally to a human.

31. A composition comprising 80.04 mg benzoate-hydrocodone conjugate, wherein the conjugate has the following structure: ##STR00028## wherein the conjugate is provided in a gel formulation.

32. The composition of claim 31 further comprising 3900 mg acetaminophen.

33. The composition of claim 31, wherein the conjugate results in the mean C.sub.max of hydrocodone of about 208,000 pg/mL.+-.87,300 pg/mL when administered orally to a human.

34. The composition of claim 31, wherein the conjugate results in the mean T.sub.max of hydrocodone of about 1.05 hours when administered orally to a human.

35. The composition of claim 31, wherein the conjugate results in the range of T.sub.max of hydrocodone from about 0.6 hours to about 4.15 hours when administered orally to a human.

36. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-0.5h of hydrocodone of about 37,140 h.times.pg/mL.+-.22,750 h.times.pg/mL when administered orally to a human.

37. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-1h of hydrocodone of about 121,900 h.times.pg/mL.+-.65,280 h.times.pg/mL when administered orally to a human.

38. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-2h of hydrocodone of about 263,500 h.times.pg/mL.+-.103,300 h.times.pg/mL when administered orally to a human.

39. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-4h of hydrocodone of about 487,500 h.times.pg/mL.+-.154,300 h.times.pg/mL when administered orally to a human.

40. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-8h of hydrocodone of about 816,300 h.times.pg/mL.+-.208,800 h.times.pg/mL when administered orally to a human.

41. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.0-24h of hydrocodone of about 1, 217, 00 h.times.pg/mL.+-.296,800 h.times.pg/mL when administered orally to a human.

42. The composition of claim 31, wherein the conjugate results in the mean AUC.sub.inf of hydrocodone of about 1,272,000 h.times.pg/mL.+-.326,500 h.times.pg/mL when administered orally to a human.

43. The composition of claim 31, wherein the conjugate results in the mean t.sub.1/2 of hydrocodone of about 5 hours.+-.1.79 hours when administered orally to a human.

44. An abuse-deterrent oral formulation comprising: a therapeutic dose of benzoate-hydrocodone conjugate hydrochloride wherein the conjugate is provided in a gel formulation that results in mean peak hydrocodone plasma concentrations (C.sub.max) and mean overall hydrocodone exposure (AUC.sub.last and AUC.sub.inf) after oral administration to a human from about 80% to about 125% when compared to an equimolar dose of hydrocodone bitartrate.

45. The composition of claim 5, wherein the gel formulation further comprises a soft gel.

46. The composition of claim 18, wherein the gel formation further comprises a soft gel.

47. The composition of claim 31, wherein the gel formation further comprises a soft gel.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.